Novartis Ag

Boehringer Ingelheim International Gmbh

Gabriela Wochnik-Veltrup

Christoph Heusser

Christoph Schwaerzler

Ingo Klagge

Stefan Hartle

Andrea Polzer

Robert Rauchenberger

Eric Borges

Paul Adam

Jose M Carballido Herrera

José M Carballido Herrera

Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.

Anti-IGF antibodies

The present invention relates to antibodies that specifically bind to IL12R&#x3b2;1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFN&#x3b3; production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN&#x3b3; production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Anti-IL12R&#x3b2;1 antibodies and their use in treating autoimmune and inflammatory disorders

Anti-IL12Rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders

The present invention relates to antibodies that specifically bind to IL12R&#x3b2;1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/1L18 induced IFN&#x3b3; production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFN&#x3b3; production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders.

Growing community of inventors

Eching a.A., Germany

Gabriela Wochnik-Veltrup